▟ Vinebot intrinsic value, daily

← back

WST West Pharmaceutical Services

healthcare · valued with opus medium conviction · deep-dived 2026-11-20

SELL
Intrinsic value$170.52
Price (at call)$396.69
Margin of safety -57.0%
vs market (rating basis) -33.7%

Recovery is real and the moat is intact, but $27.6B prices in a decade of growth injectables can't deliver.

The story

West makes elastomer stoppers, plungers and containment components for injectable drugs. Its moat is that customers write its components into their regulatory filings, so switching means requalifying with regulators. After the post-COVID destocking, revenue has picked back up (TTM $3.40B vs $3.07B in the last fiscal year). Demand from GLP-1 and biologics for higher-value components, plus EU Annex 1 rules on sterile manufacturing, is improving the product mix. It is a mature, high-quality compounder with a long but not unlimited reinvestment runway.

Facts changed modestly. TTM growth of about 11% and a 23.5% margin show recovery running ahead of my prior take, so I raised year-1 growth from 8% to 10% (a 25% relative move) and the target margin from 23.5% to 25% (mix shift to high-value components, below the 2021-22 peak). Sales-to-capital edges up to 1.15 because capex has normalized to about D&A. Beta, failure probability, terminal growth and the 10-year horizon are unchanged because the moat and life cycle are the same. Even with these upgrades, value lands well below $397. The market needs mid-teens growth sustained for a decade or margins near 30%, and neither is plausible for a component supplier this size.

Value drivers

Revenue growth (Y1)10.0%
Terminal growth3.0%
Forecast horizon10y
Target operating margin25.0%
Years to target margin5
Sales-to-capital1.15
Beta0.88
Failure probability0.8%
Cost of capital (WACC)9.0%
Terminal WACC9.5%

Valuation bridge

PV of explicit FCFF4.55B
PV of terminal value6.84B
Equity value11.88B
÷ shares → per share$170.52

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 3.74B 10.0% 23.8% 708.79M 295.37M 413.43M 379.35M
2 4.08B 9.2% 24.1% 784.07M 299.63M 484.43M 407.86M
3 4.43B 8.4% 24.4% 861.02M 299.66M 561.35M 433.65M
4 4.76B 7.7% 24.7% 938.59M 295.04M 643.55M 456.17M
5 5.09B 6.9% 25.0% 1.02B 285.43M 730.18M 474.91M
6 5.40B 6.1% 25.0% 1.08B 270.65M 807.03M 481.62M
7 5.69B 5.3% 25.0% 1.14B 250.64M 884.52M 484.34M
8 5.95B 4.6% 25.0% 1.19B 225.50M 961.36M 483.03M
9 6.18B 3.8% 25.0% 1.23B 195.52M 1.04B 477.70M
10 6.36B 3.0% 25.0% 1.27B 161.13M 1.11B 468.50M

Key risks

  • GLP-1 volume concentration and pricing pressure as pen/autoinjector formats or oral alternatives shift component demand
  • Customer destocking or biologics pipeline slowdown repeating the 2023-24 air pocket
  • Contract-manufacturing segment (Daikyo/CM) margin dilution and capex overruns on HVP capacity expansion

Catalysts

  • Sustained double-digit HVP organic growth and margin recovery above 25% in coming quarters
  • Annex 1 compliance-driven upgrades and new GLP-1 capacity coming online in 2027

History

DatePriceIntrinsicMoSRating
2026-11-20$396.69 $170.52 -57.0% SELL
2026-10-01$370.76 $139.54 -62.4% SELL
2026-08-12$351.37 $129.95 -63.0% SELL
2026-06-23$336.39 $138.65 -58.8% SELL